BRIEF-AstraZeneca begins study of breast cancer drug Faslodex

LONDON Mon Oct 29, 2012 8:09am EDT

Related Topics

LONDON Oct 29 (Reuters) - AstraZeneca PLC : * Begins a new global study of Faslodex (fulvestrant) 500 mg injection in

patients with hormone receptor-positive advanced breast cancer

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.